For patients suffering from chronic, severe back pain that hasn’t responded to traditional treatments, a spinal cord stimulator (SCS) may offer new hope.Dr. Je ...

Abbott has touted the potential of its neuromodulation portfolio in reducing patient and healthcare burdens associated with ...

Credit: Shutterstock. Study participants suffered from chronic back pain for an average of 12.8 years. The Food and Drug Administration (FDA) has expanded the approval of Abbott’s spinal cord ...

At the recently concluded North American Neuromodulation Society annual meeting, Boston presented a total of 17 abstracts.

24-month interim results from the first long-term study of SCS with automatic, objective, daily remote monitoring presented at NANS 2025 Annual Meeting This system integrates RESONANCE™ multiphase ...

DUBLIN, Aug. 25, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received CE (Conformité Européenne) Mark approval for its Inceptiv™ closed-loop ...

LAS VEGAS, Nev.--(BUSINESS WIRE)--During the scientific sessions at the 16 th Annual NANS Conference, Dr. Liong Liem, Anesthesiologist at Sint Antonius Ziekenhuis in the Netherlands and member of the ...

On May 16, 2023, the U.S. Food and Drug Administration (FDA) approved spinal cord stimulation (SCS) devices from the pharmaceutical company Abbott to treat chronic back pain in people who have not had ...